nach oben

vorheriger Artikel Skin cancer treatment options: new horizons and...

nächster Artikel Malignant melanoma: epidemiologic aspects, diag...

Tipp

Advanced basal cell carcinoma

Zeitschrift:: Wiener Medizinische Wochenschrift > Ausgabe 15-16/2013

Autoren:: MD Uwe Wollina, MD, PhD Georgi Tchernev

Summary

Basal cell carcinoma (BCC) is the most common skin malignancy worldwide. Ultraviolet light exposure is the best known exogenous factor in BCC development. This is also the target for primary prevention. Advanced BCC include locally advanced tumors and metastatic tumors. Prognosis is worse compared to stage I and II BCCs. Mohs or micrographically controlled surgery is the gold standard of treatment. In patients with tumors that cannot be completely removed radiotherapy was the only alternative in the past. More recently new drugs for targeted therapy of signaling pathways like sonic hedgehog or epidermal growth factor receptor became available. More small molecules are under investigation. Since the complete response rates are limited, future research has to evaluate their combination with surgery.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166:1069–80. PubMedCrossRef

Fartasch M, Diepgen TL, Schmitt J, Drexsler H. The relationship between occupational sun exposure and nonmelanoma skin cancer. Dtsch Ärztebl Int. 2012;109:715–20. PubMed

Wollina U. Nonmelanoma skin cancer on the rise. J Cutan Aesthet Surg. 2012;5:11. PubMed

Chinem VP, Mior HA. Epidemiology of basal cell carcinoma. An Bras Dermatol. 2011;86:292–305. PubMedCrossRef

Adinarayan M, Krishnamurthy SP. Clinicopathological evaluation of nonmelanoma skin cancer. Indian J Dermatol. 2011;56:670–2. PubMedCrossRef

Chang JM, Gao XM. Clinical and histopathological characteristics of basal cell carcinoma in Chinese patients. Chin Med J (Engl). 2013;126:211–4. PubMed

Moser S, Borm J, Michic-Probst D, Jacobsen C, Kruse-Gujer AL. Metastatic basal cell carcinoma: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013. doi:pii:S2212-4403(12)00398-7.

Greinert R, Boniol M. Skin cancer—primary and secondary prevention (information campaigns and screening)—with a focus on children & sunbeds. Progr Biophys Mol Biol. 2011;107:473–6. CrossRef

Wollina U. Addiction to tanning—a new cause of early onset of nonmelanoma skin cancer. Open Dermatol J. 2009;3:144–9. CrossRef

10.

Göppner D, Leverkus M. Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease. J Skin Cancer. 2011;2011:650258. PubMed

11.

Parren LJ, Frank J. Hereditary tumour syndromes featuring basal cell carcinomas. Br J Dermatol 2011;165:30–4. PubMedCrossRef

12.

de Vries E, Arnold M, Altsitsiadis E, Trakatelli M, Hinrichs B, Stockfleth E, et al. Potential impact of interventions resulting in reduced exposure to ultraviolet (UV) radiation (UVA and UVB) on skin cancer incidence in four European countries, 2010–2050. Br J Dermatol. 2012;167(Suppl 2):53–62. PubMedCrossRef

13.

Burnett ME, Wang SQ. Current sunscreen controversies: a critical review. Photodermatol Photoimmunol Photomed. 2011;27:58–67. PubMedCrossRef

14.

Weinstock MA, Bingham SF, Digiovanna JJ, Rizzo AE, Marcolivio K, Hall R, et al. Tretinoin and the prevention of keratinocyte carcinoma (basal and squamous cell carcinoma of the skin): a veterans affairs randomized chemoprevention trial. J Invest Dermatol. 2012;132:1583–90. PubMedCrossRef

15.

Lien MH, Fenske NA, Glass LF. Advances in the chemoprevention of nonmelanoma skin cancer in high-risk organ transplant recipients. Semin Oncol. 2012;39:134–8. PubMedCrossRef

16.

Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2010;102:1835–44. PubMedCrossRef

17.

Kasper M, Jaks V, Hohl D, Toftgård R. Basal cell carcinoma—molecular biology and potential new therapies. J Clin Invest. 2012;122:455–63. PubMedCrossRef

18.

Mancuso M, Leonardi S, Tanori M, Pasquali E, Pierdomenico M, Rebessi S, et al. Hair cycle dependent basal cell carcinoma tumorigenesis in Ptc1neo67/+mice exposed to radiation. Cancer Res. 2006;66:6606–14. PubMedCrossRef

19.

Raasch BA, Buettner PG, Garbe C. Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol. 2006;155:401–7. PubMedCrossRef

20.

Ad Hoc Task Force, Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012;67:531–50. PubMedCrossRef

21.

Narayanan K, Hadid OH, Barnes EA. Mohs micrographic surgery versus surgical excision for periocular basal cell carcinoma. Cochrane Database Syst Rev. 2012;2:CD007041. PubMed

22.

Mendenhall WM, Amdur RJ, Hinerman RW, Cognetta AB, Mendenhall NP. Radiotherapy for cutaneous squamous and basal cell carcinomas of the head and neck. Laryngoscope. 2009;119:1994–9. PubMedCrossRef

23.

Skiveren J, Mikkelsen MR, Daugberg H, Wulf HC. Skin reactions and quality of life after X-ray therapy of basal cell carcinoma. J Skin Cancer. 2012:825095.

24.

Wollina U, Schreiber A, Merla K, Haroske G. Combined cetuximab and volumetric arc-radiotherapy in advanced recurrent squamous cell carcinoma of the scalp. Dermatol Rep. 2011;3:e 57. CrossRef

25.

Bianchi L, Orlandi A, Campione E, Angeloni C, Costanzo A, Spagnoli LG, Chimenti S. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol. 2004;151:148–56. PubMedCrossRef

26.

Gaitanis G, Alexopoulos EC, Bassukas ID. Cryosurgery is more effective in the treatment of primary, nonsuperficial basal cell carcinomas when applied during and not prior to a five week imiquimod course: a randomized, prospective, open-label study. Eur J Dermatol. 2011;21:952–8. PubMed

27.

Konnikov N, Avram M, Jarell A, Tannous Z. Pulsed dye laser as a novel nonsurgical treatment for basal cell carcinomas: response and follow up 12–21 months after treatment. Lasers Surg Med. 2011;43:72–8. PubMedCrossRef

28.

Lawrence CM, Haniffa M, Dahl MG. Formalin-fixed tissue Mohs surgery (slow Mohs) for basal cell carcinoma: five-year follow-up data. Br J Dermatol. 2009;160:573–80. PubMedCrossRef

29.

Mosterd K, Krekels GA, Nieman FH, Ostertag JU, Essers BA, Dirksen CD, et al. Surgical excision versus Mohs ‘micrographic surgery for primary and recurrent basal cell carcinoma of the face: a prospective randomized controlled trial with five-years’ follow-up. Lancet Oncol. 2008;9:1149–56. PubMedCrossRef

30.

Smeets NW, Krekels GA, Ostertag JU, Essers BA, Dirksen CD, Nieman FH, et al. Surgical excision vs Mohs’ micrographic surgery for basal cell carcinoma of the face: randomized controlled trial. Lancet. 2004;364:1766–72. PubMedCrossRef

31.

Daudén E; BASALE Study Group. Effectiveness and satisfaction with imiquimod for the treatment of superficial basal cell carcinoma in daily dermatological practice. J Eur Acad Dermatol Venereol. 2011;25:1304–10. PubMedCrossRef

32.

Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrándiz C, Garcia Diez A, et al. Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle controlled phase III study in Europe. Br J Dermatol. 2005;152:939–47. PubMedCrossRef

33.

Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle controlled studies. J Am Acad Dermatol. 2004;50:722–33. PubMedCrossRef

34.

Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009;145:1431–8. PubMedCrossRef

35.

Punjabi S, Cook LJ, Kersey P, Marks R, Cerio R. Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo controlled, parallel group, multicenter study. Int J Dermatol. 2008;47:78–82. PubMedCrossRef

36.

Kowalzick L, Rogozinski T, Wimheuer R, Pilz J, Manske U, Scholz A, et al. Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study. Eur J Dermatol. 2002;12:558–61. PubMed

37.

Smucler R, Vlk M. Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma. Lasers Surg Med. 2008;40:153–8. PubMedCrossRef

38.

Souza CS, Felicio LB, Ferreira J, Kurachi C, Bentley MV, Tedesco AC, et al. Long-term follow-up of topical 5-aminolaevulinic acid photodynamic therapy diode laser single session for nonmelanoma skin cancer. Photodiagnosis Photodyn Ther. 2009;6:207–13. PubMedCrossRef

39.

Osiecka B, Jurczyszyn K, Ziółkowski P. The application of Levulan-based photodynamic therapy with imiquimod in the treatment of recurrent basal cell carcinoma. Med Sci Monit. 2012;18:I5–9. CrossRef

40.

Varga E, Korom I, Raskó E, Kis E, Varga J, Oláh J, et al. Neglected basal cell carcinomas in the twenty first century. J Skin Cancer. 2011;2011:392151. PubMed

41.

Wollina U, Pabst F, Krönert C, Schorcht J, Haroske G, Klemm E, et al. High-risk basal cell carcinoma: an update. Expert Rev Dermatol. 2010;5:357–68. CrossRef

42.

Wollina U, Helm C, Schreiber A, Brandl H-G. Extensive cranial infiltration by basal cell carcinoma. J Cutan Med Surg. 2006;10:257–8. PubMed

43.

Archontaki M, Stavrianos SD, Korkolis DP, Arnogiannaki N, Vassiliadis V, Liapakis IE, et al. Giant Basal cell carcinoma: clinicopathological analysis of 51 cases and review of the literature. Anticancer Res. 2009;29:2655–63. PubMed

44.

Wollina U, Bayyoud Y, Krönert C, Nowak A. Giant epithelial malignancies (Basal cell carcinoma, squamous cell carcinoma): a series of 20 tumors from a single center. J Cutan Aesthet Surg. 2012;5:12–9. PubMedCrossRef

45.

Lackey PL, Sargent LA, Wong L, Brzezienski M, Kennedy JW. Giant basal cell carcinoma surgical management and reconstructive challenges. Ann Plast Surg. 2007;58:250–4. PubMedCrossRef

46.

Leibovitch I, McNab A, Sullivan T, Davis G, Selva D. Orbital invasion by periocular basal cell carcinoma. Ophthalmology. 2005;112:717–23. PubMedCrossRef

47.

Kleydman Y, Manolidis S, Ratner D. Basal cell carcinoma with intracranial invasion. J Am Acad Dermatol. 2009;60:1045–9. PubMedCrossRef

48.

Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990;8:342–6. PubMed

49.

Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Perez S, Lopez-Saura P, Bello-Rivero I. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer. 2009;9:262. PubMedCrossRef

50.

Mevio N, Bertino G, Occhini A, Scelsi D, Tagliabue M, Mura F, Benazzo M. Electrochemotherapy for the treatment of recurrent head and neck cancers: preliminary results. Tumori. 2012;98:308–13. PubMed

51.

Wollina U, Hansel G, Koch A, Köstler E. Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. J Cancer Res Clin Oncol. 2005;131:300–4. PubMedCrossRef

52.

Wollina U. Cetuximab in nonmelanoma skin cancer. Expert Opin Biol Ther. 2012;12:949–56. PubMedCrossRef

53.

Kalapurakal SJ, Malone J, Robbins KT, Buescher L, Godwin J, Rao K. Cetuximab in refractory skin cancer treatment. J Cancer. 2012;3:257–61. PubMedCrossRef

54.

Caron J, Dereure O, Kerob D, Lebbe C, Guillot B. Metastatic basal cell carcinoma: report of two cases treated with cetuximab. Br J Dermatol. 2009;161:702–3. PubMedCrossRef

55.

Müller H, Eisendle K, Gastl G, Höpfl R, Zelger B. Palliative therapy of giant basal cell carcinoma with the monoclonal antiepidermal growth factor receptor antibody cetuximab. Br J Dermatol. 2008;158:1386–8. PubMedCrossRef

56.

Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal cell carcinoma. N Engl J Med. 2009;361:1164–72. PubMedCrossRef

57.

LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17:2502–11. PubMedCrossRef

58.

Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal cell nevus syndrome. N Engl J Med. 2012;366:2180–8. PubMedCrossRef

59.

Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal cell carcinoma. N Engl J Med. 2012;366:2717–9. CrossRef

60.

Fellner C. Vismodegib (Erivedge) for advanced basal cell carcinoma. PT. 2012;37(12):670–82.

61.

Stanton BZ, Peng LF. Small molecule modulators of the sonic hedgehog signaling pathway. Mol Biosyst. 2010;6:44–54. PubMedCrossRef

62.

Tang JY, Marghoob AA. Emerging treatments and signaling pathway inhibitors. Semin Cutan Med Surg. 2011;30(Suppl 4):14–8. CrossRef

63.

Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, et al. Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23:23–34. PubMedCrossRef

64.

Fu J, Rodova M, Roy SK, Sharma J, Singh KP, Srivastava RK, et al. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett. 2013;330:22–32. PubMedCrossRef

65.

Lauth M, Bergström A, Shimokawa T, Toftgård R. Inhibition of GLI mediated transcription and tumor cell growth by small molecule antagonists. Proc Natl Acad Sci U S A. 2007;104:8455–60. PubMedCrossRef

66.

Chenna V, Hu C, Pramanik D, Aftab BT, Karikari C, Campbell NR, et al. A polymeric nanoparticle encapsulated small molecule inhibitor of hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to smoothened antagonists. Mol Cancer Ther. 2012;11:165–73. PubMedCrossRef

Titel: Advanced basal cell carcinoma
Autoren:: MD Uwe Wollina
MD, PhD Georgi Tchernev
Publikationsdatum: 01.08.2013
DOI: https://doi.org/10.1007/s10354-013-0193-5
Verlag: Springer Vienna
Zeitschrift: Wiener Medizinische Wochenschrift
Ausgabe 15-16/2013
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 15-16/2013

Malignant melanoma: epidemiologic aspects, diagnostic and therapeutic approach

Cutaneous side effects of vemurafenib: a case report and discussion

Skin cancer treatment options: new horizons and promises for the future

Atypical fibroxanthoma—a diagnosis of exclusion!

Cetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients

Merkelzellkarzinom: eine Überprüfung und Aktualisierung über die Pathogenese, Diagnose und Therapieansätze